Table of Contents

Key Takeaways

  • Jardiance A1C lowering effect is around 0.7%-0.8% over 24 weeks, while Mounjaro can reduce blood sugar levels by up to 2.4% over 40 weeks.
  • In clinical trials, participants taking Jardiance lost approximately 2.8%-3.2% of their body weight by week 24. In comparison, patients treated with Mounjaro lost about 6.3kg -7.8 kg by week 40 of therapy, roughly 9% of their total body weight.
  • Jardiance is FDA-approved to reduce the risk of kidney disease progression, cardiovascular death, and hospitalization.
  • In the SUMMIT clinical trial, tirzepatide — the active ingredient in Mounjaro — was shown to reduce the risk of worsening heart failure events or cardiovascular death by 38% compared with placebo.
  • Jardiance commonly causes urinary tract infections and genital yeast infections, while Mounjaro typically causes digestive side effects like nausea and vomiting.

Both Jardiance and Mounjaro are FDA-approved for treating type 2 diabetes. If you’re comparing Jardiance vs. Mounjaro, you’ve probably wondered which one is better for long-term health. These medications work in very different ways, and that difference matters. So which one is stronger? Which is safer? And which makes more sense for your specific health goals in 2026?

Quick Answer: Who Should Choose Which?

Choose Mounjaro if you:

    • Need aggressive weight loss (more than 15% of your body weight)
    • Struggle with appetite control
    • A1C is very high (more than 8.5%)
    • Comfortable with a once-weekly injection
    • Do not have significant GI sensitivity or a history of pancreatitis

Choose Jardiance if you:

    • Have heart-related conditions, such as heart failure
    • Have chronic kidney disease
    • Prefer a pill
    • Prone to gastrointestinal side effects
    • Want a more affordable option to manage diabetes

How Do Jardiance and Mounjaro Work?

Hand holding a Jardiance package

Jardiance contains empagliflozin, which works by helping your kidneys remove extra glucose from your body through urine. The medication comes as a daily pill that you take once in the morning. It’s approved for adults and children 10 years of age and older with type 2 diabetes, making it one of the few newer diabetes medications available for younger patients. Is Jardiance a GLP-1? No, belongs to a class of diabetes medications called SGLT2 inhibitors.

Jardiance Health Benefits

Jardiance offers several benefits beyond just managing glucose levels:

    • Heart protection: Proven to reduce major cardiovascular events
    • Kidney benefits: Helps slow kidney function decline
    • Modest weight loss: Typically results in 2.8%-3.2% weight reduction

Mounjaro contains tirzepatide, which mimics two natural hormones — GIP and GLP-1 — to reduce appetite and control blood sugar levels. It works by slowing how quickly food moves through your stomach and reducing hunger signals. Mounjaro comes as a once-weekly injection and is approved only for adults with type 2 diabetes.

Mounjaro Health Benefits

Mounjaro’s dual action provides several effects:

    • Blood sugar control: Can lower A1C by up 2.4% in 40 weeks.
    • Significant weight loss: Can facilitate weight loss by 15%-20% of baseline weight, with some people achieving up to 22%
    • Heart protection: Can reduce the risk of serious heart failure events or cardiovascular death by 38%.

9 Key Differences of Jardiance vs. Mounjaro

Feature Jardiance (Empagliflozin) Mounjaro (Tirzepatide)
1. Drug Class SGLT2 inhibitor Dual GIP/GLP-1 receptor agonist
2. Form Oral once-daily tablet Weekly subcutaneous injection
3. Mechanism of Action Promotes urinary glucose excretion and reduces blood pressure Mimics two gut hormones to stimulate insulin secretion and reduce appetite
4. A1C Reduction 0.7% to 0.8% Up to 2.4%
5. Average Weight Loss 2.8% to 3.2% 10%-20% depending on dose
6. Heart Protection Proven reduction in cardiovascular death and heart failure hospitalization (EMPA-REG OUTCOME) Proven cardiovascular benefit (SUMMIT trial)
7. Kidney Protection Approved to slow chronic kidney disease progression Emerging evidence suggests potential benefit
8. Common Side Effects Urinary tract infection, yeast infections, dehydration Nausea, vomiting, gastrointestinal intolerance
9. Average USA price $737 $1,159

Clinical Trial Results: Which Is Better for Diabetes, Weight Loss, Kidney & Heart Disease?

Compare Mounjaro vs. Jardiance in terms of their effects on blood sugar, weight loss, and cardiovascular health.

A1C Reduction 

    • Mounjaro: Across SURPASS-1 through SURPASS-5, tirzepatide consistently lowered average blood sugar levels in patients with type 2 diabetes. Some patients decreased their A1C by 1.7%-2.4% from baseline across various doses when compared with control groups.
    • Jardiance: In an FDA-reviewed clinical trial, empagliflozin decreased A1C by approximately 0.7%-0.8% over 24 weeks, compared with a 0.1% reduction in patients receiving placebo.

Weight Loss

    • Mounjaro: Up to 22.5% or 23.6 kg (52 lbs) weight loss in the SURMOUNT-1 trial. Higher doses of tirzepatide were associated with higher weight loss.
    • Jardiance: 2.8%-3.2% body weight loss in FDA clinical trials. Jardiance was associated with modest weight loss.

Cardiovascular Protection

    • Mounjaro: In the SUMMIT trial involving 713 patients across 9 countries (including the US), tirzepatide reduced cardiovascular death or worsening heart failure by 38%.
    • Jardiance: In the EMPA-REG OUTCOME trial that involved 7,020 patients with type 2 diabetes and established cardiovascular disease, empagliflozin was shown to significantly reduce the risk of cardiovascular death by approximately 38% compared with placebo.

Kidney Protection

  • Emerging renal data for tirzepatide in SURPASS 1-5 clinical trials: Exploratory data from tirzepatide studies suggest potential benefits on markers of kidney function, such as slower eGFR decline and reductions in urinary albumin-to-creatinine ratio.
  • Jardiance approved for CKD: Empagliflozin is approved for use in chronic kidney disease (CKD) and has demonstrated reductions in kidney disease progression and heart failure hospitalizations in adults with and without diabetes.

Summary of Outcomes from Clinical Trials

Outcome Mounjaro Jardiance
A1C Reduction Up to 2.4% 0.7% to 0.8%
Weight loss Up to 22.5% 2.8%-3.2%
Heart benefits Reduced cardiovascular death or worsening heart failure by 38%. Lowered the risk of cardiovascular death by approximately 38% compared with placebo
CKD progression Emerging Strong evidence; FDA-approved

Which is better for diabetes? Mounjaro, because it significantly reduces HbA1c compared with an SGLT2 like Jardiance.

Which is better for weight loss? When comparing Mounjaro vs. Jardiance for weight loss, Mounjaro can help you lose more weight because it directly targets appetite.

Your doctor may likely recommend Mounjaro for type 2 diabetes, but if you have a co-existing kidney condition, Jardiance may be a safer option because it protects the kidneys.

Side Effects Compared

Mounjaro’s side effects are primarily digestive:

    • Most common adverse reactions include diarrhea, nausea, constipation, and vomiting
    • Generally mild to moderate gastrointestinal effects during the first 4-8 weeks
    • Rare but serious side effects include acute pancreatitis, diabetes-related vision loss, acute kidney injury, and acute gallbladder disease

Jardiance side effects are related to increased glucose in urine:

    • Urinary tract infections (more common in females than males)
    • Genital yeast infections (affecting 5.4-6.4% of females and 1.6-3.1% of males)
    • Increased urination, especially when starting treatment
    • Rare cases of diabetic ketoacidosis (DKA), particularly in patients with low insulin reserve or during illness or surgery.

Many side effects improve with time as your body adjusts to the medication. Staying well-hydrated is important with either option.

Which Has More Serious Risks?

Both medications have serious risks that require monitoring. Certain people may be predisposed to each drug’s serious risks:

With Jardiance:

    • History of dehydration
    • Low blood pressure
    • Prone to ketones or eating less
    • Concurrent diuretic use
    • Impaired renal function

With Mounjaro:

    • Prior pancreatitis
    • Gallbladder disease
    • Severe GI sensitivity
    • Personal or family history of medullary thyroid carcinoma (MEN2)

Can You Take Jardiance and Mounjaro Together?

Yes, you can take Mounjaro and Jardiance together if your doctor recommends it. Because they work through different mechanisms, combining them may improve blood sugar control, preserve kidney function, and support heart health. However, monitoring is important, especially if you also use insulin or sulfonylureas.

A1C and Weight Loss “Stacking” Effect

Mounjaro controls blood sugar by activating dual GIP/GLP-1 receptors. Jardiance blocks SGLT2 in the kidneys, allowing excess sugar to be excreted in the urine. Because these medications target different pathways, combining them can:

    • Improve overall glycemic control: Mounjaro alone can reduce A1C by up to 2.4% while Jardiance typically lowers A1C by up to 0.8%.
    • Enhance weight loss: Mounjaro promotes significant weight loss, which benefits patients living with obesity.
    • Provide added heart and kidney protection (from Jardiance): For patients with diabetes and co-occurring heart and kidney conditions.

In certain cases, there’s no need to compare Jardiance vs. Mounjaro for weight loss or diabetes because your doctor may combine them. The combination makes it safe in patients with poorly controlled type 2 diabetes or multiple cardiometabolic risk factors.

Hypoglycemia or Severe Low Blood Sugar Risk

Neither Mounjaro nor Jardiance typically causes hypoglycemia on their own. However, the risk increases when either is combined with:

    • Insulin
    • Sulfonylureas (e.g., glipizide, glimepiride)

When all three are used together, dose adjustments may be necessary to prevent blood sugar from dipping too low.

When Doctors Prefer One Over the Other

Endocrinologists typically prioritize lowering A1C levels and losing weight. For patients with high blood sugar or obesity, endocrinologists may prefer Mounjaro because of its stronger glucose-lowering and weight-reduction effects. However, if cardiovascular disease or kidney protection is a major concern, an SGLT2 inhibitor may be layered in or chosen first.

Cardiologists may prefer Jardiance in patients with established cardiovascular disease. This is because empagliflozin is FDA-approved for reducing the risk of cardiovascular death and heart failure hospitalization.

Obesity specialists may prescribe Mounjaro if the priority is weight loss and the patient struggles with controlling their appetite. Tirzepatide’s dual GIP/GLP-1 mechanism results in greater weight loss than SGLT2 inhibitors, making it more effective for obesity.

Cost Comparison in 2026

Cost is a huge factor for many patients when choosing between Jardiance and Mounjaro.

Without insurance, the 2026 average retail price of Mounjaro in the U.S. is approximately $1,159 per month, compared with about $737 for Jardiance.

Actual cash prices may vary based on:

    • Pharmacy pricing differences
    • Geographic location
    • Dose strength
    • Availability of discount programs

Jardiance generally falls into a lower retail tier compared to Mounjaro. It’s also more broadly covered because it has FDA approvals for multiple conditions — type 2 diabetes, heart failure, and chronic kidney disease. Mounjaro is only approved for type 2 diabetes.

Eli Lilly and Boehringer Ingelheim, the manufacturers of these medications, offer savings cards and copay assistance programs that can help reduce costs if you qualify.

When comparing Mounjaro vs. Jardiance cost, Mounjaro is typically more expensive without insurance coverage. With insurance, Jardiance may be easier to obtain due to broader FDA indications.

Some patients look into purchasing prescriptions through licensed Canadian pharmacies, where pricing can be substantially lower depending on the medication and dosage.

Bottom Line — Jardiance or Mounjaro?

When comparing Jardiance vs. Mounjaro, the better option depends on your primary health goal. If you need substantial A1C reduction and significant weight loss, Mounjaro may offer stronger benefits. If heart failure, cardiovascular protection, or kidney disease is a major concern, Jardiance has more established outcome data in those areas.

The decision typically comes down to key health markers, such as your current A1C level, BMI, co-existing conditions, tolerance to side effects, and insurance coverage.

In some cases, doctors may even prescribe Mounjaro and Jardiance together for complementary benefits. Ultimately, the right choice should be based on your full medical history, risk profile, and treatment goals. Your doctor will create a personalized plan to make sure your chosen treatment is safe and effective.

Buy Mounjaro from Canada

Starting from $499.97

Ready to Buy Mounjaro Online?

Choose BuyCanadianInsulin.com for affordable medications such as Mounjaro and take control of your health with reliable, cost-effective options today!

SAVE 10% with coupon code:

MOUNJARO10

Frequently Asked Questions

Mounjaro lowers A1C more, with average reductions of up to 2.4% in clinical trials, compared with roughly 0.6%-0.8% for Jardiance.
On their own, neither drug commonly causes hypoglycemia, but the risk increases when combined with insulin or sulfonylureas.
No, Jardiance is a prescription oral tablet, not an injection.
Jardiance is generally preferred for heart failure because it has strong outcome data and FDA approval for reducing heart failure hospitalizations.
Jardiance commonly causes urinary and genital infections, while Mounjaro’s side effects are mainly gastrointestinal, including nausea, vomiting, and diarrhea.
Yes, doctors sometimes prescribe them together because they work through different mechanisms, but monitoring is important to reduce dehydration and low blood sugar risk.
Jardiance is typically favored for chronic kidney disease because it is approved to slow CKD progression, whereas Mounjaro’s renal benefits are still emerging.
Yes, triple therapy with metformin, Jardiance, and Mounjaro is sometimes used for uncontrolled Type 2 diabetes, provided kidney function and hydration are monitored.
Yes, Jardiance can cause modest weight loss, typically around 2–3% of body weight, due to increased glucose excretion in urine.
Ozempic is a good alternative to Mounjaro. It contains semaglutide, a mono-agonist approved by the FDA for diabetes. Like Mounjaro, it promotes weight loss as a secondary benefit.
Weight loss on Jardiance occurs because the body eliminates excess glucose (and calories) through urine, and greater calorie loss can lead to more noticeable weight reduction in some people.
Yes, patients can switch under medical supervision, especially if stronger A1C reduction or weight loss is needed.
Ozempic typically lowers A1C and weight more than Jardiance, but Jardiance may be preferred for heart failure or kidney protection.
The main downsides include increased risk of genital infections, dehydration, and rare cases of diabetic ketoacidosis.
No, Jardiance is an SGLT2 inhibitor taken daily as a pill, while Mounjaro is a weekly injectable dual GIP/GLP-1 receptor agonist with stronger glucose and weight effects.

Sources

  1. U.S. Food and Drug Administration. NOVOLOG (insulin aspart) injection prescribing information. February 2023. View source
  2. U.S. Food and Drug Administration. Drugs@FDA: NovoLog (Application 020986) product listing. Accessed November 2026. View source
  3. U.S. Food and Drug Administration. HUMALOG (insulin lispro) injection prescribing information. May 2025. View source
  4. U.S. Food and Drug Administration. FDA-Approved Insulin Products: Rapid-Acting Insulins. Accessed November 2026. View source
  5. Eli Lilly and Company. HUMALOG Mix75/25 prescribing information. Accessed November 2026. View source
  6. Health Canada. NovoRapid product monograph. May 2026. View source
  7. Medicare.gov. Insulin coverage. Accessed November 2026. View source
  8. S. Food and Drug Administration. Biosimilar Product Information. Updated October 28, 2026. View source

Last updated: November 2026.